Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19339212 | 1.00 | MAPK1 (0.34) | MAPK1LMNAPOLBALDH1A1TSHR | |
| SCHEMBL17459553 | 1.00 | MAPK1 (0.34) | MAPK1LMNAPOLBALDH1A1TSHR | |
| SCHEMBL17468555 | 1.00 | MAPK1 (0.34) | MAPK1LMNAPOLBALDH1A1TSHR | |
| SCHEMBL601379 | 0.90 | LMNA (0.33) | MAPK1LMNAPOLBALDH1A1TSHR | |
| SCHEMBL19339296 | 0.88 | POLB (0.32) | MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL19339360 | 0.85 | EPHX2 (0.33) | MAPK1LMNAPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL19339299 | 0.81 | POLB (0.30) | POLBALDH1A1CYP2C19KMT2A | |
| SCHEMBL22167302 | 0.77 | ALDH1A1 (0.30) | ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL12366305 | 0.77 | LMNA (0.36) | MAPK1LMNAPOLBALDH1A1TSHR | |
| SCHEMBL10486140 | 0.77 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MAPK1 683/4885LMNA 2896/4885POLB 4737/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MAPK1 683/4885LMNA 2896/4885POLB 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.